{"id":"NCT02023099","sponsor":"AbbVie","briefTitle":"Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) in Japanese Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection","officialTitle":"A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) in Treatment-Naïve and Treatment-Experienced Japanese Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection With and Without Compensated Cirrhosis (GIFT I)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-12","primaryCompletion":"2014-10","completion":"2015-10","firstPosted":"2013-12-30","resultsPosted":"2015-11-26","lastUpdate":"2018-06-06"},"enrollment":363,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Hepatitis C Infection"],"interventions":[{"type":"DRUG","name":"ABT-450/r/ABT-267","otherNames":["ABT-267 also known as ombitasvir","ABT-450 also known as paritaprevir","ritonavir also known as Norvir","VIEKIRAX Combination Tablets","Qurevo","Technivie","VIEKIRA Combination Tablets"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Substudy 1, Arm A: DB 2-DAA","type":"EXPERIMENTAL"},{"label":"Substudy 1, Arm B: DB Placebo, Followed by OL 2-DAA","type":"PLACEBO_COMPARATOR"},{"label":"Substudy 2, Arm C: OL 2-DAA","type":"EXPERIMENTAL"}],"summary":"This is a phase 3, double-blinded, multicenter study. The study will consist of 2 substudies: Substudy 1 (SS1) will be double-blinded and enroll non-cirrhotic subjects and Substudy 2 (SS2) will be open label and enroll subjects with compensated cirrhosis.","primaryOutcome":{"measure":"Percentage of Non-cirrhotic Treatment-Naïve Participants Who Are Eligible for Interferon (IFN)-Based Therapy and Who Have High Viral Load in the DB Active Treatment Group With a Sustained Virologic Response 12 Weeks Post-treatment","timeFrame":"12 weeks after the last dose of study drug","effectByArm":[{"arm":"Substudy 1, Arm A: DB 2-DAA","deltaMin":94.6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":3},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["26147154","27084721"],"seeAlso":["http://rxabbvie.com"]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":215},"commonTop":["NASOPHARYNGITIS","HEADACHE","OEDEMA PERIPHERAL","PRURITUS","DIARRHOEA"]}}